Lv5
820 积分 2023-11-16 加入
ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival
4个月前
已关闭
Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies
9个月前
已完结
KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia
11个月前
已完结
Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment
11个月前
已完结
Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia
1年前
已完结
皖公网安备34019202002308
